Antibody combination could help stop close contacts getting COVID-19
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
A combination of antibodies could help stop COVID-19 from spreading to close contacts of known COVID-19 cases, according to US research. The antibody combination, known as REGEN-COV, or a placebo were given to people within 96 hours of a household contact receiving a COVID-19 diagnosis. The study found that symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGENCOV group (1.5 per cent) and in 59 of 752 participants in the placebo group (7.8 per cent). Among those who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load.
Journal/conference: New England Journal of Medicine
Link to research (DOI): 10.1056/NEJMoa2109682
Organisation/s: Regeneron Pharmaceuticals
Attachments:
Note: Not all attachments are visible to the general public
